Almirall SA, wani kamfani na biopharmaceutical na duniya da ke mayar da hankali kan lafiyar fata, ya sanar a yau ƙaddamar da kasuwancin Turai na Wynzora® cream (50 µg / g calcipotriol da 0.5 mg / g betamethasone a matsayin dipropionate), wanda aka haɓaka don maganin cututtukan cututtukan fata mai laushi zuwa matsakaicin plaque psoriasis a ciki. manya har da fatar kai. Spain, Jamus, da Birtaniya sune ƙasashen Turai na farko inda ake samun kirim don takardar sayan magani. Bayan ƙaddamar da wannan m Topical Topical, Almirall ya zama kawai biopharmaceutical kamfanin a Turai don bayar da psoriasis marasa lafiya da yawa zažužžukan rufe dukan bakan cutar, daga Topical zuwa na baka tsarin da ilmin halitta.
Wynzora® Cream yana da ƙarfi ta hanyar Fasaha ta PAD, sabuwar hanyar haɗa man fetur da ruwa, wanda ya sa shi kawai calcipotriene da betamethasone dipropionate Topical wanda ke ba da damar haɗuwa da kayan aiki masu aiki a cikin kirim mai ruwa. Fasaha tana ba da damar tsayayyen tsari kuma yana ba da ingantaccen bayanin martaba da jin daɗin haƙuri.
Wynzora® yana ba da ingantaccen inganci da saurin aiwatar da aiki a cikin mako 1. Sakamakon binciken da aka tattara na gwaje-gwaje na Phase III guda biyu bazuwar ya nuna cewa wannan CAL / BDP PAD-cream yana ba da ingantaccen inganci da ingancin rayuwa mai haƙuri a cikin jiyya na psoriasis idan aka kwatanta da calcipotriene da betamethasone dipropionate gel tsari don duk ingantaccen ƙarshen ƙarshen ciki har da. Nasarar jiyya na PGA, mPASI, da PASI75 bayan makonni 8 na amfani da rana sau ɗaya.
Binciken na asibiti ya kuma nuna cewa, bayan makonni takwas na jiyya, yawancin batutuwa da aka bi da su tare da CAL / BDP PAD-cream sun ruwaito cewa psoriasis ba shi da wani tasiri a rayuwarsu (DLQI 0 ko 1) idan aka kwatanta da CAL / BDP gel. . Karɓar mai haƙuri na CAL/BDP PAD-cream ya kasance ne musamman saboda abin da ake magana da shi kasancewar ƙaramin tsari mai ƙima dangane da sabuwar fasahar PAD. Sakamakon daga gwajin gwaji na Phase III an buga shi a cikin Journal of the European Academy of Dermatology and Venereology (JEADV).
Psoriasis yana daya daga cikin cututtukan fata da suka fi yaduwa a duniya, yana shafar kusan mutane miliyan 100 a duk duniya da kuma kusan kashi 1.52% na al'ummar Burtaniya (mutane miliyan 1.01 aka kiyasta). Yana da mummunan tasiri akan ingancin rayuwa kuma yana wakiltar babban nauyi a cikin rayuwar yau da kullun na 71% na marasa lafiya, yana shafar yanayin jin daɗin rai na 88% na mutanen da ke fama da yanayin. "A cikin 'yan shekarun nan mun lura da ɗimbin ci gaba a cikin jiyya da ake samu don psoriasis, duk da haka, riko da jiyya na cikin gida ya ragu. Zuwan sabon tsarin PAD-cream na CAL / BDP labari ne mai kyau ga al'ummar psoriasis, waɗanda yanzu suna da zaɓin magani wanda ya haɗu da inganci da bayanin martaba na ingantaccen kayan aikin CAL / BDP a cikin sabuwar fasahar abin hawa don haƙuri. dacewa,” in ji Farfesa Anthony Bewley, Mashawarcin Likitan fata, UK.
Fitar da Wynzora® Cream don ci gaba a cikin sauran Turai a cikin 2022
Almirall ya fara tallan Wynzora® Cream a cikin Burtaniya, Spain da Jamus a farkon wannan watan kuma yana tsammanin fitowa a wasu ƙasashen Turai a cikin watanni masu zuwa, da zarar an ba da izinin tallan na ƙasa. Samfurin ya sami amincewar tsari a Jamhuriyar Czech, Denmark, Faransa, Jamus, Netherlands, Norway, Spain, Sweden, UK, Finland, Portugal, Italiya da Ireland tare da sunan Wynzora®, kuma tare da sunan Winxory® a Austria.
"Kaddamar da Wynzora® Cream a Turai yana wakiltar mataki na gaba a cikin sadaukarwarmu don ba da sababbin hanyoyin kwantar da hankali waɗanda ke inganta rayuwar marasa lafiya tare da psoriasis. A halin yanzu, kashi 73% na marasa lafiya ba sa bin jiyya na zahiri [4]. Dangane da wannan rashin kulawa da irin waɗannan jiyya, Almirall ya tabbata cewa wannan sabon samfurin, tare da ingantaccen inganci da tsari na abokantaka na haƙuri, zai nuna alamar juyi ta hanyar inganta gamsuwar marasa lafiya na psoriasis godiya ga ƙarancin ƙirar sa, "in ji shi. Gianfranco Nazzi, Babban Jami'in Almirall.
"Kaddamar da Wynzora ® Cream a cikin ƙasashen Turai ya nuna wani ci gaba a cikin samfurin duniya na duniya. Wannan kirim alama ce ta mahimman kaddarorin ƙirar ƙira da tsarin bayarwa na PAD Technology. An tsara shi tare da buri don samar da farawa da sauri da inganci, ingantaccen bayanin martabar aminci da babban dacewa da gamsuwa da marasa lafiya a cikin ayyukan yau da kullun a cikin samfur guda ɗaya. Mun yi imani da sauki da riko da sabon inganci, "in ji Jesper J. Lange, Shugaba na MC2 Therapeutics, mai haɓaka fasahar PAD.
A cikin Fabrairu 2021, Almirall da MC2 Therapeutics sun shiga yarjejeniya mai mahimmanci wacce MC2 Therapeutics ta ba wa Almirall haƙƙin Turai keɓantacce don tallata Wynzora® Cream don maganin plaque psoriasis. Kamfanonin biyu sun ba da sanarwar nasarar kammala tsarin raba gardama a watan Yuli 2021. Wani kamfani kuma yana sayar da kirim ɗin a Amurka.
